"uuid:ID","id","versionIdentifier","rationale","instanceType"
"58821a56-fc7e-4639-8cb7-137a2b43cb2c","StudyVersion_1","2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion"
